BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21119513)

  • 21. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
    Bernicker E
    Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
    [No Abstract]   [Full Text] [Related]  

  • 22. Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?
    Galetta D; Rossi A; Colucci G; Gebbia V
    Oncology; 2009; 77 Suppl 1():113-21. PubMed ID: 20130439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomere length, telomeric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metastases.
    Raynaud CM; Mercier O; Commo F; Dartevelle P; Gomez-Roca C; de Montpreville V; Sabatier L; Soria JC
    Lung Cancer; 2009 Aug; 65(2):144-9. PubMed ID: 19091442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array.
    Hofmann HS; Bartling B; Simm A; Murray R; Aziz N; Hansen G; Silber RE; Burdach S
    Oncol Rep; 2006 Sep; 16(3):587-95. PubMed ID: 16865260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics.
    Radtke J; Rezaie SG; Kugler Ch; Zabel P; Schultz H; Vollmer E; Goldmann T; Lang DS
    Rom J Morphol Embryol; 2010; 51(4):647-53. PubMed ID: 21103621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular targeted therapy in lung cancer.
    Fujioka N; Bitterman PB
    Minn Med; 2012 Oct; 95(10):38-41. PubMed ID: 23193704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMGA2 overexpression in non-small cell lung cancer.
    Meyer B; Loeschke S; Schultze A; Weigel T; Sandkamp M; Goldmann T; Vollmer E; Bullerdiek J
    Mol Carcinog; 2007 Jul; 46(7):503-11. PubMed ID: 17477356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
    Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
    Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized therapy for non-small cell lung cancer: hype or clinical reality?
    Wigle DA
    Semin Thorac Cardiovasc Surg; 2011; 23(1):30-5. PubMed ID: 21807296
    [No Abstract]   [Full Text] [Related]  

  • 33. Lung cancer biomarkers: present status and future developments.
    Cagle PT; Allen TC; Olsen RJ
    Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.
    Johnson ML; Patel JD
    Semin Oncol; 2014 Feb; 41(1):93-100. PubMed ID: 24565583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of BRCA1 in non-small cell lung cancer.
    Gachechiladze M; Skarda J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Sep; 156(3):200-3. PubMed ID: 23069884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.
    Nogueira A; Assis J; Catarino R; Medeiros R
    Pharmacogenomics; 2013 Apr; 14(6):689-700. PubMed ID: 23570471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
    Codacci-Pisanelli G; Frati L; Mini E
    J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular prognostication of non-small cell lung cancer.
    Tsao MS; Jablons DM
    Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
    [No Abstract]   [Full Text] [Related]  

  • 40. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?
    Booton R; Blackhall F; Kerr K
    Thorax; 2011 Apr; 66(4):273-5. PubMed ID: 21345972
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.